Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2011-11-02 Earnings Release
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir offentliggör slutresultat från TMC435 fas IIb-studien ASPIRE (C206)
Earnings Release Classification · 99% confidence The document is a press release dated November 2, 2011, announcing the final results from the TMC435 phase IIb clinical study (ASPIRE) for Hepatitis C treatment. It details efficacy data (SVR24 rates) and safety profiles, and also mentions results from another study (DRAGON). Crucially, it announces a conference call for analysts and investors to discuss these results. This structure—a formal announcement of key financial/clinical results followed by details and a call invitation—is characteristic of an Earnings Release (ER) or a general announcement of significant news. Since the content is focused on clinical trial results which are material to the company's valuation and future, and it is presented as a 'Pressmeddelande' (Press Release) announcing these findings, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical/material financial/operational results. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or just a presentation (IP). It is the initial release of material operational/clinical data. FY 2011
2011-11-02 Swedish
Medivir Announces Final Results from TMC435 Phase IIb ASPIRE (C206) Study
Earnings Release Classification · 95% confidence The document is explicitly titled "Press Release 2 November 2011" and announces the "Final Results from TMC435 Phase IIb ASPIRE (C206) Study." It details clinical trial efficacy and safety data, which are key components of financial and operational reporting for a pharmaceutical company. Since it is a press release announcing specific, periodic financial/operational results (clinical trial outcomes), it aligns best with the Earnings Release (ER) category, which covers initial announcements of periodical results, even if this specific result is clinical rather than purely financial. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). It is a direct announcement of results, not just an announcement that a report is forthcoming (RPA/RNS). FY 2011
2011-11-02 English
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period 1 January – 30 September 2011. It contains comprehensive financial statements, including income statements, balance sheet summaries, and management commentary on business performance, R&D, and future outlook. It is not a mere announcement (RPA) as it provides the full financial data and analysis for the specified period. 9M 2011
2011-10-24 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report, 1 January – 30 September 2011' and contains comprehensive financial statements, including consolidated profit performance tables, balance sheet data, and detailed management commentary on business segments and R&D. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2011
2011-10-24 English
Major Shareholding Notification 2011
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (FMR LLC) in the issuer (Medivir Aktiebolag). It explicitly mentions 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage (9.91%). This structure perfectly matches the definition of a Major Shareholding Notification, which is classified as 'MRQ' in the provided schema.
2011-10-14 English
Medivir offentliggör att fyra TMC435-abstrakt accepterats för presentation på AASLD:s möte
Investor Presentation Classification · 90% confidence The document is a press release dated September 30, 2011, announcing that four abstracts related to the drug candidate TMC435 have been accepted for presentation at the AASLD meeting. It details the results of a Phase 2b study (PILLAR) and lists the titles of the oral and poster presentations. This type of announcement, which publicizes upcoming scientific presentations or the release of preliminary/detailed study data outside of a formal regulatory filing (like 10-K or IR), is best classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it were summarizing financial results. Since this is a specific announcement about scientific data presentation and includes detailed tables and study descriptions, it functions as a communication aimed at investors and analysts regarding clinical progress. However, given the options, it is not a formal financial report (10-K, IR, ER), nor is it a general regulatory filing (RNS). It is a detailed update on clinical trial progress, which often accompanies or precedes an Investor Presentation or is a standalone scientific update. Since it is a detailed communication of study results and upcoming presentations, it aligns closely with the nature of an Investor Presentation (IP) which often includes such scientific data, or potentially an Earnings Release (ER) if the company considers this material to be part of its periodic results disclosure, although it lacks typical quarterly financial summaries. Given the focus on clinical trial data presentation, 'Investor Presentation' (IP) is the most fitting category for this type of detailed scientific/pipeline update released via press release, even though it's an announcement *about* presentations, it conveys the core information intended for investors. If the document were purely announcing the *publication* of a report without the content, it would be RPA/RNS. Since it contains the core data/abstract summaries, IP is chosen over the general RNS/RPA.
2011-09-30 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.